ERBB2 and gastric cancer: On the basis of RATIONALE-305, the NMPA approved a combined therapy of tislelizumab in combination with certain types of chemotherapy (XELOX or FP: 5-fuorouracil and cisplatin) for the initial treatment of patients with advanced or metastatic GC or GEJC (non-HER2-positive tumors) [6].